• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233 ALIGN TO URETHRAL SUPPORT SYSTEM - HALO; ALIGN® TO URETHRAL SUPPORT SYSTEM - HALO

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (COVINGTON) -1018233 ALIGN TO URETHRAL SUPPORT SYSTEM - HALO; ALIGN® TO URETHRAL SUPPORT SYSTEM - HALO Back to Search Results
Model Number BRD500HL
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Abdominal Pain (1685); Adhesion(s) (1695); Erosion (1750); Diarrhea (1811); High Blood Pressure/ Hypertension (1908); Nausea (1970); Pain (1994); Abnormal Vaginal Discharge (2123); Anxiety (2328); Discomfort (2330); Prolapse (2475); Abdominal Cramps (2543); Intermenstrual Bleeding (2665); Dyspareunia (4505); Urinary Incontinence (4572)
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The reported event could not be confirmed.No sample was returned for evaluation.Based on the investigation findings, current manufacturing controls are considered adequate as to detect and segregate any non-conforming unit.Event described could not be confirmed as a manufacturing related issue.The alleged event is most likely associated with possible procedural/surgical complications.The ifu currently addresses potential risks associated with surgically implantable materials which states the following: precautions: the usual precautions associated with urological procedures should be followed: accepted surgical practice and precautions must be followed for the management of contaminated or infected wound sites, when the align¿ to urethral support system is used.Postoperative bleeding may occur in some patients and must be controlled prior to patient release.The implant procedure requires diligent attention to anatomical structure and care to avoid puncture of large vessels, nerves, bladder, and any viscera, during introducer needle passage.Proper placement of the mesh sling implant at mid-urethra requires that it lies flat with minimal or no tension under the urethra.The align¿ to urethral support system is intended as a single-use, disposable device.Do not resterilize any portion of the align¿ to urethral support system.Patients should be advised that pregnancy following a mesh sling implant procedure may negatively affect the success of the previous implant procedure and incontinence may reoccur.The safety and effectiveness of the align¿ to urethral support system implant procedure has not been established for the treatment of stress urinary incontinence in males and children under the age of 18.Cystoscopy can be considered at the physician¿s discretion.Do not use the align¿ to urethral support system if the packaging is opened or damaged.After use, this product may be a potential biohazard.Handle and dispose of in accordance with accepted medical practice and applicable local, state and federal laws and regulations.Adverse events: complications associated with the proper implantation of the align¿ to urethral support system may include, but are not limited to: postoperative hematoma, which may occur following the implant procedure temporary urinary retention, bladder outlet obstruction, and voiding difficulties associated with over correction/too much tension placed on the mesh sling implant perforations or lacerations of vessels, nerves, bladder or any viscera, which may occur during introducer needle passage transitory irritation at the operative wound site, which may elicit a foreign body response that leads to inflammation, infection, or erosion of the implant.1750="l"; 1928, 2475, 2993="nl".
 
Event or Problem Description
The patient's attorney alleged a deficiency against the device.Per additional information received via medical records on 15oct2021, the patient has experienced stress urinary incontinence, pelvic organ prolapse, cystocele, rectocele, vaginal pain, dryness, pelvic pain, mesh erosion, dyspareunia, extrusion, abdominal cramps, bloody vaginal discharge, urinary leakage, mixed incontinence, nocturia, enuresis, incomplete emptying of bladder, anxiety, hypertension, hypercholesterolemia, acute vaginitis, adhesions, metromenorrhagia, uterine fibroids, menstrual bleeding, dysmenorrhea, vaginal spotting, acute appendicitis, abdominal pain, nausea, discomfort, loss of appetite, diarrhea and required additional surgical and non-surgical interventions.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ALIGN TO URETHRAL SUPPORT SYSTEM - HALO
Common Device Name
ALIGN® TO URETHRAL SUPPORT SYSTEM - HALO
Manufacturer (Section D)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
MDR Report Key12703525
Report Number1018233-2021-80082
Device Sequence Number4613994
Product Code OTN
UDI-Device Identifier00801741016226
UDI-Public(01)00801741016226
Combination Product (Y/N)N
Initial Reporter StateTX
Initial Reporter CountryUS
PMA/510(K) Number
K093747
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2008
Reporter Type Manufacturer
Report Source other
Initial Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date (Section B) 10/27/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date07/31/2008
Device Model NumberBRD500HL
Device Catalogue NumberBRD500HL
Device Lot NumberCVRG0038
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Device Age9 MO
Event Location Hospital
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 10/15/2021
Initial Report FDA Received Date10/27/2021
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age40 YR
-
-